Kastenmayer James Paul 4
4 · Aeglea BioTherapeutics, Inc. · Filed Aug 25, 2022
Insider Transaction Report
Form 4
Kastenmayer James Paul
Interim CEO & General Counsel
Transactions
- Award
Employee Stock Option (right to buy)
2022-08-23+130,000→ 130,000 totalExercise: $0.68Exp: 2032-08-22→ Common Stock (130,000 underlying)
Footnotes (1)
- [F1]The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48 of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested.